• Record: found
  • Abstract: found
  • Article: not found

Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke.

Stroke; a Journal of Cerebral Circulation

Treatment Outcome, Double-Blind Method, Fibrinolytic Agents, therapeutic use, Humans, Logistic Models, Models, Biological, Models, Statistical, Sensitivity and Specificity, Stroke, diagnosis, drug therapy, Thrombolytic Therapy, Time Factors, Tissue Plasminogen Activator

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      The clinical-diffusion mismatch (CDM) model has been proposed as a simpler tool than perfusion-diffusion mismatch (PDM) to select acute ischemic stroke patients for thrombolytic therapy. We hypothesized that in the 3- to 6-hour time window, the effect of tPA was significantly greater in patients with CDM than in patients without CDM. This is a substudy of EPITHET, a double-blind multi-center study of 100 patients randomized to tPA or placebo 3 to 6 hours after stroke onset. MRI was obtained before treatment, and at 3 to 5 days and 90 days after treatment. Presence of PDM (perfusion deficit/DWI(volume) >1.2 and perfusion deficit at least 10 mL>DWI(volume)) and CDM (NIHSS >or=8 and DWI(volume) or=8 points between baseline and 90 days, or a 90-day NIHSS

      Related collections

      Author and article information



      Comment on this article